cytarabine - CISMeF

Preferred Label : cytarabine;

MeSH definition : A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472);

MeSH synonym : aracytidine; arabinofuranosylcytosine; arabinosylcytosine; arabinoside, cytosine; cytosine arabinoside;

CISMeF synonym : 69-74-9 (Cytarabine hydrochloride); CytosarU; hydrochloride, cytarabine;

MeSH hyponym : cytonal; Cytarabine Hydrochloride; cytosar; beta-Ara C; aracytine; Ara-C; beta Ara C; Cytosar-U; Cytosar U; Ara C;

MeSH CAS label : 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-;

MeSH Related Number : cytarabine hydrochloride; 147-94-4 (Cytarabine); 69-74-9 (HCl); 33K3DB6591;

Registry Number MeSH : 147-94-4;

Related CAS MeSH : 33K3DB6591 (Cytarabine hydrochloride);

Wikipedia link : https://en.wikipedia.org/wiki/Cytarabine;

Codes EINECS : 205-705-9;

Is substance : O;

UNII : 04079A1RDZ;

InChIKey : UHDGCWIWMRVCDJ-CCXZUQQUSA-N;

Details

Origin ID

D003561;

UMLS CUI

C0010711;

ATC code(s)
- cytarabine [ATC Code]
- cytarabine and daunorubicin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Cytarabine adverse reaction (disorder) [SNOMED CT concept]
- cytarabine [Substance BNPC]
Currated CISMeF NLP mapping
- Cytarabine [ICD-11 Extension code]
- Cytarabine [LOINC component]
- Cytarabine [ICHI extension code]
- Cytarabine [SMS substance]
- Cytarabine [NCIt concept]
- Cytarabine (substance) [SNOMED CT concept]
- Poisoning caused by cytarabine (disorder) [SNOMED CT concept]
- cytarabine [SNOMED Notion]
Pharmacological action(s)
- antimetabolites, antineoplastic [MeSH Descriptor]
- antiviral agents [MeSH Descriptor]
- immunosuppressive agents [MeSH Descriptor]
Record concept(s)
- Ara-C [MeSH concept]
- Cytarabine Hydrochloride [MeSH concept]
- aracytine [MeSH concept]
- beta-Ara C [MeSH concept]
- cytarabine [MeSH concept]
- cytonal [MeSH concept]
- cytosar [MeSH concept]
Related MeSH Supplementary Concept(s)
- (18F)1-(2'-deoxy-2'-arabinofuranosyl)cytosine [MeSH Supplementary Concept]
- (99m)Tc-N4-(hydrazinonicotinoyl)-1-beta-arabinofuranosyl cytosine [MeSH Supplementary Concept]
- 1 beta-D-arabinofuranosylcytosine 5'-diphosphate-L-1,2 dipalmitin [MeSH Supplementary Concept]
- 1 beta-D-arabinofuranosylcytosine diphosphate choline [MeSH Supplementary Concept]
- 1 beta-D-arabinofuranosylcytosine-5'-diphosphate cortisol [MeSH Supplementary Concept]
- 1 beta-arabinofuranosylcytosine 5'-diphosphate-1,2-diolein [MeSH Supplementary Concept]
- 1(beta)-D-arabinofuranosylcytosine-5'-diphosphate prednisolone [MeSH Supplementary Concept]
- 1(beta)-arabinofuranosylcytosine 5'-diphosphate-1,2-distearin [MeSH Supplementary Concept]
- 1-(2'-deoxy-2'-fluoro-arabinofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(2-O-methyl-beta-D-arabinofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(2-O-nitro-beta-D-arabinofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(2-chloro-2-deoxy-D-arabinofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(2-deoxy-2-C-fluoromethylarabinofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(2-deoxy-2-C-hydroxymethylarabinofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(2-deoxy-2-fluoro-4-thio-arabinofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(3-deoxypentofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-(5-deoxy-beta-D-hexofuranosyl)cytosine [MeSH Supplementary Concept]
- 1-arabinofuranosyl-5-ethynylcytosine [MeSH Supplementary Concept]
- 1-beta-4-selenoarabinofuranosyl cytosine [MeSH Supplementary Concept]
- 2',5'-arabinosylcytidine monophosphate [MeSH Supplementary Concept]
- 2'-cyano-2'-deoxyarabinofuranosylcytosine [MeSH Supplementary Concept]
- 2'-deoxy-2'-fluoro-4'-selenoarabinofuranosylcytosine [MeSH Supplementary Concept]
- 2'-deoxy-5-fluorouridylyl-(5'-5')-N(4)-octadecyl-1-arabinofuranosylcytosine [MeSH Supplementary Concept]
- 2'-fluoro-5-bromo-1-beta-D-arabinofuranosylcytosine [MeSH Supplementary Concept]
- 2'-fluoro-5-chloro-1-beta-D-arabinofuranosylcytosine [MeSH Supplementary Concept]
- 2'-fluoro-5-methylarabino-furanosylcytosine [MeSH Supplementary Concept]
- 2,2'-anhydro-1-(3'-O-acetyl-beta-arabinofuranosyl)-5-iodocytosine [MeSH Supplementary Concept]
- 3'-O-galactopyranosyl-1-4-O-galactopyranosylcytarabine [MeSH Supplementary Concept]
- 3'-O-galactopyranosylcytarabine [MeSH Supplementary Concept]
- 4'-azidoarabinocytidine [MeSH Supplementary Concept]
- 4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone [MeSH Supplementary Concept]
- 5'-chloro-5'-deoxyarabinosylcytosine [MeSH Supplementary Concept]
- 5'-oleoyl cytarabine [MeSH Supplementary Concept]
- 5'-palmitoyl cytarabine [MeSH Supplementary Concept]
- 5-fluoro-2'-deoxyuridylyl-(3'-5')-arabinocytidine [MeSH Supplementary Concept]
- 5-methyl ara-C [MeSH Supplementary Concept]
- 7+3 protocol [MeSH Supplementary Concept]
- A-TRIPLE-V protocol [MeSH Supplementary Concept]
- AA1-3 protocol [MeSH Supplementary Concept]
- AAABC protocol [MeSH Supplementary Concept]
- AB-triple V protocol [MeSH Supplementary Concept]
- ABCDV protocol [MeSH Supplementary Concept]
- ABEP protocol 1 [MeSH Supplementary Concept]
- ACE protocol 2 [MeSH Supplementary Concept]
- ACMP protocol [MeSH Supplementary Concept]
- ACOMLA protocol [MeSH Supplementary Concept]
- ACT protocol [MeSH Supplementary Concept]
- ADA protocol [MeSH Supplementary Concept]
- ADOAP protocol [MeSH Supplementary Concept]
- AFC regimen [MeSH Supplementary Concept]
- AIEOP acute lymphoblastic leukemia protocol [MeSH Supplementary Concept]
- ALHR88 protocol [MeSH Supplementary Concept]
- ALL-82 protocol [MeSH Supplementary Concept]
- ALL-85 protocol [MeSH Supplementary Concept]
- ALL-BFM-95 protocol [MeSH Supplementary Concept]
- AML8A protocol [MeSH Supplementary Concept]
- AML91 protocol [MeSH Supplementary Concept]
- AML92 protocol [MeSH Supplementary Concept]
- AMSA-OAP protocol [MeSH Supplementary Concept]
- ANLL91 protocol [MeSH Supplementary Concept]
- AOAP protocol [MeSH Supplementary Concept]
- ARA-COP protocol [MeSH Supplementary Concept]
- ASHAP protocol [MeSH Supplementary Concept]
- ATA protocol [MeSH Supplementary Concept]
- B-8801 protocol [MeSH Supplementary Concept]
- B-DOMP protocol [MeSH Supplementary Concept]
- B-triple-V protocol [MeSH Supplementary Concept]
- BACT protocol [MeSH Supplementary Concept]
- BAEC protocol [MeSH Supplementary Concept]
- BAVC protocol [MeSH Supplementary Concept]
- BEAM protocol [MeSH Supplementary Concept]
- BEAM regimen [MeSH Supplementary Concept]
- BF-9 protocol [MeSH Supplementary Concept]
- BFM 78 protocol [MeSH Supplementary Concept]
- BFM-86 protocol [MeSH Supplementary Concept]
- BFM-ALL 81 protocol [MeSH Supplementary Concept]
- BGM 84 protocol [MeSH Supplementary Concept]
- BH-AC-AMP protocol [MeSH Supplementary Concept]
- BH-AC-DMP protocol [MeSH Supplementary Concept]
- BHAC-AMP protocol [MeSH Supplementary Concept]
- BHAC-DMPV protocol [MeSH Supplementary Concept]
- BMF phase II protocol [MeSH Supplementary Concept]
- BMVC protocol [MeSH Supplementary Concept]
- BVAM protocol [MeSH Supplementary Concept]
- Berlin-Frankfurt-Muenster protocol II [MeSH Supplementary Concept]
- CAG protocol [MeSH Supplementary Concept]
- CAMELEON protocol [MeSH Supplementary Concept]
- CAMP combination [MeSH Supplementary Concept]
- CARA protocol [MeSH Supplementary Concept]
- CARE protocol [MeSH Supplementary Concept]
- CART protocol [MeSH Supplementary Concept]
- CAT combination [MeSH Supplementary Concept]
- CAT-G protocol [MeSH Supplementary Concept]
- CEF regimen [MeSH Supplementary Concept]
- CHASE protocol [MeSH Supplementary Concept]
- CLAG protocol [MeSH Supplementary Concept]
- COA protocol [MeSH Supplementary Concept]
- COAP protocol [MeSH Supplementary Concept]
- COMET-A protocol [MeSH Supplementary Concept]
- COMLA protocol [MeSH Supplementary Concept]
- CONB-A protocol [MeSH Supplementary Concept]
- COPAD protocol [MeSH Supplementary Concept]
- CPX-351 [MeSH Supplementary Concept]
- CROP protocol [MeSH Supplementary Concept]
- CT protocol [MeSH Supplementary Concept]
- CTR III protocol [MeSH Supplementary Concept]
- CVAP-B protocol [MeSH Supplementary Concept]
- CYM protocol [MeSH Supplementary Concept]
- D(A)AT protocol [MeSH Supplementary Concept]
- D-ZAPO protocol [MeSH Supplementary Concept]
- DAEP protocol [MeSH Supplementary Concept]
- DAP protocol [MeSH Supplementary Concept]
- DAT protocol 1 [MeSH Supplementary Concept]
- DAT-COAP regimen [MeSH Supplementary Concept]
- DATOP protocol [MeSH Supplementary Concept]
- DATV regimen [MeSH Supplementary Concept]
- DAV regimen [MeSH Supplementary Concept]
- DCMP protocol [MeSH Supplementary Concept]
- DCTER protocol [MeSH Supplementary Concept]
- DCTP regimen [MeSH Supplementary Concept]
- DCVP-1-asp protocol [MeSH Supplementary Concept]
- DHACT protocol [MeSH Supplementary Concept]
- DHAOx protocol [MeSH Supplementary Concept]
- DHAP protocol [MeSH Supplementary Concept]
- DOA protocol [MeSH Supplementary Concept]
- DOAPP protocol [MeSH Supplementary Concept]
- Dexa-BEAM protocol [MeSH Supplementary Concept]
- Dexa-PAMB protocol [MeSH Supplementary Concept]
- DoVA protocol [MeSH Supplementary Concept]
- EDAP regimen [MeSH Supplementary Concept]
- EORTC GIMEMA AML-10 protocol [MeSH Supplementary Concept]
- EORTC GIMEMA AML-13 protocol [MeSH Supplementary Concept]
- ESA protocol [MeSH Supplementary Concept]
- ESAP protocol [MeSH Supplementary Concept]
- ESHAP regimen [MeSH Supplementary Concept]
- ESHAP regimen, modified [MeSH Supplementary Concept]
- EVAP regimen [MeSH Supplementary Concept]
- EVDAC regimen [MeSH Supplementary Concept]
- F-MACHOP protocol [MeSH Supplementary Concept]
- FLAG protocol [MeSH Supplementary Concept]
- FLAM regimen [MeSH Supplementary Concept]
- FLANG protocol [MeSH Supplementary Concept]
- FLUDAP protocol [MeSH Supplementary Concept]
- G-IDEA protocol [MeSH Supplementary Concept]
- GAP-POMP regimen [MeSH Supplementary Concept]
- GEMIA protocol [MeSH Supplementary Concept]
- GIMEMA ALL 0394 [MeSH Supplementary Concept]
- HAD protocol [MeSH Supplementary Concept]
- HAT regimen [MeSH Supplementary Concept]
- HCVAD protocol [MeSH Supplementary Concept]
- HDAC protocol [MeSH Supplementary Concept]
- HOAAP protocol [MeSH Supplementary Concept]
- HOAGP protocol [MeSH Supplementary Concept]
- HOAP protocol [MeSH Supplementary Concept]
- HOAP-Bleo protocol [MeSH Supplementary Concept]
- HR-1 protocol [MeSH Supplementary Concept]
- HR-3 protocol [MeSH Supplementary Concept]
- HiC-COM protocol [MeSH Supplementary Concept]
- ICE protocol 4 [MeSH Supplementary Concept]
- IVAC protocol [MeSH Supplementary Concept]
- IVAM regimen [MeSH Supplementary Concept]
- Ida-FLAG protocol [MeSH Supplementary Concept]
- L-6 protocol [MeSH Supplementary Concept]
- L-valyl-ara-C [MeSH Supplementary Concept]
- LAI regimen [MeSH Supplementary Concept]
- LLA-IV-AR protocol [MeSH Supplementary Concept]
- LMB89 protocol [MeSH Supplementary Concept]
- LPA97R protocol [MeSH Supplementary Concept]
- LSA(2)L(2) protocol [MeSH Supplementary Concept]
- MAC chemotherapy protocol [MeSH Supplementary Concept]
- MAC conditioning regimen [MeSH Supplementary Concept]
- MACHO protocol [MeSH Supplementary Concept]
- MAD protocol [MeSH Supplementary Concept]
- MAMI protocol [MeSH Supplementary Concept]
- MATILDE regimen [MeSH Supplementary Concept]
- MAV protocol [MeSH Supplementary Concept]
- MB-triple V protocol [MeSH Supplementary Concept]
- MCP 842 regimen [MeSH Supplementary Concept]
- MDACC protocol [MeSH Supplementary Concept]
- MEA protocol [MeSH Supplementary Concept]
- MECA protocol [MeSH Supplementary Concept]
- MFC protocol [MeSH Supplementary Concept]
- MI-MIV maintenance protocol [MeSH Supplementary Concept]
- MIFAP regimen [MeSH Supplementary Concept]
- MINE-ESHAP protocol [MeSH Supplementary Concept]
- MLL-93 protocol [MeSH Supplementary Concept]
- MOPLACE protocol [MeSH Supplementary Concept]
- MRC AML 10 protocol [MeSH Supplementary Concept]
- MiCMA protocol [MeSH Supplementary Concept]
- Murphy-Bowmann protocol [MeSH Supplementary Concept]
- N(4)-(4-carboxybutyryl)-1-arabinofuranosylcytosine-polylysine conjugate [MeSH Supplementary Concept]
- N(4)-(4-carboxybutyryl)-1-beta-arabinofuranosylcytosine [MeSH Supplementary Concept]
- N(4)-chloroacetylcytosine arabinoside [MeSH Supplementary Concept]
- N(4)-hexadecyl-1-arabinofuranosylcytosine [MeSH Supplementary Concept]
- N(4)-octadecyl-1-arabinofuranosylcytosine [MeSH Supplementary Concept]
- N(4)-oleoyl cytarabine [MeSH Supplementary Concept]
- N(4)-oleylcytosine arabinoside [MeSH Supplementary Concept]
- N(4)-palmitoyl cytarabine [MeSH Supplementary Concept]
- N(4)-succinyl-1-beta-D-arabinofuranosylcytosine [MeSH Supplementary Concept]
- N4-(4-carboxybutyryl)-1-arabinofuranosylcytosine-decylenediamine-dextran T70 [MeSH Supplementary Concept]
- N4SE protocol [MeSH Supplementary Concept]
- NOAC protocol [MeSH Supplementary Concept]
- OAP protocol [MeSH Supplementary Concept]
- OAP-Bleo protocol [MeSH Supplementary Concept]
- PACET protocol [MeSH Supplementary Concept]
- PAE protocol [MeSH Supplementary Concept]
- PAME protocol [MeSH Supplementary Concept]
- PATCO protocol [MeSH Supplementary Concept]
- PETHEMA ALL-3-97 protocol [MeSH Supplementary Concept]
- POCAL protocol [MeSH Supplementary Concept]
- POG 8493 protocol [MeSH Supplementary Concept]
- POG 8602 protocol [MeSH Supplementary Concept]
- POG-8498 protocol [MeSH Supplementary Concept]
- POMB-ACE protocol [MeSH Supplementary Concept]
- PROMACE-CytaBOM protocol [MeSH Supplementary Concept]
- ProMECE-CytaBOM protocol [MeSH Supplementary Concept]
- RACOP protocol [MeSH Supplementary Concept]
- RAP protocol [MeSH Supplementary Concept]
- RATE protocol [MeSH Supplementary Concept]
- ROAP protocol [MeSH Supplementary Concept]
- T-8801 protocol [MeSH Supplementary Concept]
- TA protocol [MeSH Supplementary Concept]
- TACC protocol [MeSH Supplementary Concept]
- TAM protocol [MeSH Supplementary Concept]
- TAPA protocol [MeSH Supplementary Concept]
- TAVE protocol [MeSH Supplementary Concept]
- TGAP protocol [MeSH Supplementary Concept]
- TOAP protocol [MeSH Supplementary Concept]
- TOTAL-XII protocol [MeSH Supplementary Concept]
- TRAMPCO protocol [MeSH Supplementary Concept]
- TRAMPCOL protocol [MeSH Supplementary Concept]
- UCH I protocol [MeSH Supplementary Concept]
- UCH II protocol [MeSH Supplementary Concept]
- VAAP regimen [MeSH Supplementary Concept]
- VABA protocol [MeSH Supplementary Concept]
- VAC combination [MeSH Supplementary Concept]
- VAD regimen [MeSH Supplementary Concept]
- VAE protocol [MeSH Supplementary Concept]
- VAMA protocol [MeSH Supplementary Concept]
- VAPA protocol [MeSH Supplementary Concept]
- VAPAC protocol [MeSH Supplementary Concept]
- VATA protocol [MeSH Supplementary Concept]
- VIM3-ARA C regimen [MeSH Supplementary Concept]
- VINAP protocol [MeSH Supplementary Concept]
- VMP-CIsCF protocol [MeSH Supplementary Concept]
- adamantoylcytarabine [MeSH Supplementary Concept]
- ara-C 5'-benzoate [MeSH Supplementary Concept]
- ara-C 5'octanoate [MeSH Supplementary Concept]
- ara-CDP-1-O-octadecyl-2-O-palmitoyl-sn-glycerol [MeSH Supplementary Concept]
- ara-CDP-1-S-hexadecyl-2-O-palmitoyl-1-thioglycerol [MeSH Supplementary Concept]
- ara-CDP-1-S-octadecyl-2-O-palmitoyl-1-thioglycerol [MeSH Supplementary Concept]
- ara-fluorocytosine [MeSH Supplementary Concept]
- araC-diphosphate diglyceride [MeSH Supplementary Concept]
- aracytidine-5'-hexadecylphosphonophosphate [MeSH Supplementary Concept]
- carboxymethyl-beta-glucan-cytarabine [MeSH Supplementary Concept]
- chitosan-N(4)-(4-carboxybutyryl)-1-arabinofuranosylcytosine conjugate [MeSH Supplementary Concept]
- cortisol-4-ara-C [MeSH Supplementary Concept]
- cortisone-4-ara-C [MeSH Supplementary Concept]
- cyclic ara-CMP [MeSH Supplementary Concept]
- cytarabine 5'-methylphosphonate [MeSH Supplementary Concept]
- cytaramin [MeSH Supplementary Concept]
- cytarazid [MeSH Supplementary Concept]
- cytosine arabinoside palmitate [MeSH Supplementary Concept]
- elaidic acid-cytarabine [MeSH Supplementary Concept]
- enocitabine [MeSH Supplementary Concept]
- fiacitabine [MeSH Supplementary Concept]
- n-squalenoyl-cytarabine [MeSH Supplementary Concept]
- new york protocol [MeSH Supplementary Concept]
- polygalacturonic acid-cytarabine [MeSH Supplementary Concept]
- protocol 8001 [MeSH Supplementary Concept]
See also
- Decitabine [MeSH Descriptor]
Semantic type(s)
- Nucleic Acid, Nucleoside, or Nucleotide [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Cytarabine [ICD-11 Extension code]
- Cytarabine [LOINC component]
- Cytarabine [NCIt concept]
- Cytarabine (substance) [SNOMED CT concept]
- Product containing cytarabine (medicinal product) [SNOMED CT concept]
- cytarabine [ATC Code]
- cytarabine [Substance BNPC]
- cytarabine [SNOMED Notion]
Validated automatic mappings to BTNT
- 1-.beta.-d-arabinofuranosylcytosine hydrochloride [Substance BNPC]
- Cytarabine Hydrochloride [NCIt concept]
- Cytarabine hydrochloride [SMS substance]
- cytarabine [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients